RedHill Biopharma and Canadian drug delivery company IntelGenx have signed a license agreement with Spanish company Grupo JUSTE for the marketing of Rizaport in Spain, along with a right of first refusal for additional territories.

Rizaport is a proprietary oral thin film formulation of rizatriptan used for the treatment of patients with acute migraines.

Under the deal, Grupo JUSTE has received the exclusive rights to register and commercialise RedHill Biopharma’s Rizaportin Spain.

The company has also been granted the right of first refusal for a predefined term for the territories of Belize, the Carribbean, Colombia, Costa Rica, Chile, Dominican Republic, El Salvador, Guatemala, Honduras, the Middle East, Mexico, Nicaragua, Panama and Morocco.

"Under the deal, Grupo JUSTE has received the exclusive rights to register and commercialise RedHill Biopharma’s Rizaportin Spain."

RedHill business development and licensing senior vice-president Adi Frish said: "We are delighted to enter into this first commercialisation agreement for Rizaport and look forward to building a long-term relationship with Grupo JUSTE in support of their efforts to introduce Rizaport in Spain, along with potentially other Latin American (LATAM) and Middle Eastern territories.

"We believe that, thanks to the pleasant flavouring and convenient use of the rapidly dissolving thin-film, Rizaport could potentially become a preferred therapeutic option for migraine patients worldwide."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The initial term of the deal is for ten years from the date of the first commercial sale and will automatically renew for another term of two years.

Rizaport is expected to be commercially launched in Spain in the second half of next year. Financial terms of the agreement have not been disclosed.

Rizaport 5mg and 10mg has recently been granted marketing authorisation by the Federal Institute for Drugs and Medical Devices of Germany (BfArM) under the European Decentralised Procedure (DCP).

The authorisation was the first marketing approval ever received for Rizaport in Germany.